The partnership will include $105m upfront to Orionis, with the potential for further payments that could exceed $2bn.

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the Roche Group (OTCQX:RHHBY). The goal of this partnership is to discover ...

Orionis Biosciences Inc. is sticking with Genentech Inc. in a second deal to discover small-molecule monovalent glue ...

Roche, along with Bristol Myers Squibb, Novo Nordisk, AbbVie, Eli Lilly and others, is making inroads into molecular glues to use in cancer, immunology and other applications.

Roche's Genentech is sticking with Orionis Biosciences, handing over $105 million upfront as part of its second deal with the molecular glue biotech. The latest multiyear collaboration will be ...

Orionis announced its first collaboration with Genentech, to discover novel small-molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration ...

The multiyear licensing pact with Orionis Biosciences will use the Boston-based biotech’s Allo-Glue platform to discover and optimize molecular glues for targets designated by Genentech.

Orionis Biosciences, a privately held company, announced a second multi-year collaboration with Genentech, a member of the Roche Group (OTCQX:RHHBY) on Wednesday. The goal of this partnership is ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech, focusing on the discovery and development of small-molecule monovalent glue medicines for difficult targets in ...